Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02700373 · ClinicalTrials.gov registry record · Phase 1
A Phase I, Single-Center Study of PDC-APB in Healthy Volunteers
A Phase 1 study of Contact Dermatitis, sponsored by Hapten Sciences.
- Completed
- Registry status
- Phase 1
- Development phase
- 40
- Enrollment target
- 1
- Study location
NCT02700373 is a Phase 1 study of Contact Dermatitis that has completed, run by Hapten Sciences. The registered enrollment target is 40 participants, below the 139-participant average among 3 other Contact Dermatitis trials with a reported enrollment target (71% lower). The trial reports 1 study location across 1 state.
The verdict
NCT02700373, a Phase 1 study of Contact Dermatitis, has completed, sponsored by Hapten Sciences.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 40 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a randomized, double-blind, placebo-controlled, single ascending dose study to assess the safety and tolerability of PDC-APB by intramuscular (IM) injection compared to placebo.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG PDC-APB
Study Locations (1)
Tennessee
- Clinical Research Solutions - Franklin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2016-03 |
| Est. Completion | 2018-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02700373
The ClinicalTrials.gov registry entry for NCT02700373 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 139-participant average among 3 other Contact Dermatitis trials with a reported enrollment target (71% lower). The listed sponsor is Hapten Sciences, which has 1 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Contact Dermatitis appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT02700373 reports 1 study location spanning 1 distinct geographic area - top geographies include Tennessee.
Frequently Asked Questions
What is clinical trial NCT02700373 about?
NCT02700373 is a clinical study titled "A Phase I, Single-Center Study of PDC-APB in Healthy Volunteers". This is a randomized, double-blind, placebo-controlled, single ascending dose study to assess the safety and tolerability of PDC-APB by intramuscular (IM) injection compared to placebo.
What is the current status of trial NCT02700373?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 40 participants. The study started on 2016-03. Estimated completion is 2018-01.
What conditions does trial NCT02700373 study?
This clinical trial studies the following conditions: Contact Dermatitis.
What interventions are being tested in trial NCT02700373?
The interventions under investigation include: Placebo (DRUG), PDC-APB (DRUG).
Who is sponsoring clinical trial NCT02700373?
This trial is sponsored by Hapten Sciences, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02700373 being conducted?
This trial has 1 study location across Tennessee. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Contact Dermatitis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.